Some of them are approved for the treatment of breast and ovarian cancer, for example, olaparib (trade name Lynparza). The proposed method makes it possible to describe the mechanism of clinical ...

Olaparib is an investigational is a first-in ... monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company ...

"Our precision medicine approach allows us to target the underlying resistance mechanisms to AR-targeted ... in combination with abiraterone acetate, olaparib or 177Lu-PSMA-617, in adults with ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

The first patent has been dosed in the phase 1b/2a clinical trial P300-02-001, which is evaluating pocenbrodib alone, and in combination with Zytiga (abiraterone acetate), Lynparza (olaparib ... the ...

Now LP-300's mechanism, which enhances the efficacy of ... where we evaluate a combination regimen with the PARP inhibitor olaparib. In our preclinical work, we saw tremendous synergy between ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Future Planned Phase 1b/2 Trials: Lantern has submitted a clinical trial protocol to the FDA for a Phase 1b/2 study in TNBC evaluating a combination regimen with the PARP inhibitor, Olaparib.

PARP inhibitors exploit vulnerabilities in cancer cells’ DNA repair mechanisms, particularly in patients with BRCA mutations. Drugs like olaparib and talazoparib have shown promise in clinical ...